Axsome Therapeutics (AXSM) PT Set at $13.00 by Cantor Fitzgerald

Axsome Therapeutics (NASDAQ:AXSM) has been assigned a $13.00 price target by stock analysts at Cantor Fitzgerald in a research note issued on Friday. The firm presently has a “buy” rating on the stock. Cantor Fitzgerald’s target price indicates a potential upside of 146.21% from the company’s previous close.

Separately, Zacks Investment Research upgraded Axsome Therapeutics from a “hold” rating to a “buy” rating and set a $6.25 price target on the stock in a report on Tuesday, September 26th. One investment analyst has rated the stock with a sell rating and five have given a buy rating to the company. Axsome Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $16.70.

Axsome Therapeutics (NASDAQ:AXSM) opened at $5.28 on Friday. Axsome Therapeutics has a twelve month low of $3.53 and a twelve month high of $7.20. The company has a debt-to-equity ratio of 0.44, a current ratio of 3.86 and a quick ratio of 3.86.

A number of hedge funds have recently made changes to their positions in AXSM. Goldman Sachs Group Inc. acquired a new position in Axsome Therapeutics during the first quarter valued at approximately $121,000. LMR Partners LLP bought a new stake in shares of Axsome Therapeutics in the second quarter valued at approximately $206,000. Sphera Funds Management LTD. boosted its position in shares of Axsome Therapeutics by 24.9% in the second quarter. Sphera Funds Management LTD. now owns 501,000 shares of the company’s stock valued at $2,756,000 after acquiring an additional 100,000 shares during the period. Susquehanna International Group LLP bought a new stake in shares of Axsome Therapeutics in the second quarter valued at approximately $188,000. Finally, JPMorgan Chase & Co. boosted its position in shares of Axsome Therapeutics by 1.6% in the third quarter. JPMorgan Chase & Co. now owns 1,459,117 shares of the company’s stock valued at $8,026,000 after acquiring an additional 23,229 shares during the period. Institutional investors own 25.39% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This article was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this article on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The correct version of this article can be accessed at https://www.com-unik.info/2017/12/03/axsome-therapeutics-axsm-pt-set-at-13-00-by-cantor-fitzgerald.html.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain.

What are top analysts saying about Axsome Therapeutics Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Axsome Therapeutics Inc and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit